Can a Three-Drug cocktail calm a suicidal crisis in days?

NCT ID NCT06133114

Terminated Disease control Sponsor: Icahn School of Medicine at Mount Sinai Source: ClinicalTrials.gov ↗

First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time

Summary

This trial tests whether giving a combination of clonazepam, olanzapine, and buprenorphine for just two days can quickly relieve the intense emotional distress of Suicide Crisis Syndrome in hospitalized adults. Participants are randomly assigned to receive one, two, or three of these medications, or standard care. The goal is to see if the drug pulses can reduce distress and suicidal thoughts by the time of discharge and one month later.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: clonazepam, olanzapine, and buprenorphine, alone or in combination
What this could lead to: If successful, this could point toward a fast-acting medication strategy to reduce acute emotional distress and suicide risk in hospitalized patients.
What could go wrong: This is a small early-phase trial, and the medications have side effects such as drowsiness, dizziness, and risk of dependence. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSYCHOLOGICAL DISTRESS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PSYCHOLOGICAL DISTRESS SUICIDE CRISIS SYNDROME

Contacts and locations

Locations

Icahn School of Medicine at Mount Sinai

New York, New York, 10029, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.